-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
BioRestorative Therapies (OTCMKTS:BRTX) Earns Buy Rating From Analysts at Roth Capital
BioRestorative Therapies (OTCMKTS:BRTX) Earns Buy Rating From Analysts at Roth Capital
Roth Capital initiated coverage on shares of BioRestorative Therapies (OTCMKTS:BRTX – Get Rating) in a research report sent to investors on Wednesday, The Fly reports. The firm issued a buy rating and a $15.00 price target on the stock.
Separately, Maxim Group initiated coverage on BioRestorative Therapies in a report on Wednesday, September 28th. They issued a buy rating on the stock.
Get BioRestorative Therapies alerts:BioRestorative Therapies Price Performance
OTCMKTS BRTX opened at $3.16 on Wednesday. BioRestorative Therapies has a 1-year low of $2.46 and a 1-year high of $6.25. The business's fifty day moving average price is $3.16 and its 200-day moving average price is $3.27.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in BioRestorative Therapies stock. Cambridge Investment Research Advisors Inc. bought a new position in BioRestorative Therapies, Inc. (OTCMKTS:BRTX – Get Rating) during the first quarter, according to its most recent disclosure with the SEC. The firm bought 23,001 shares of the company's stock, valued at approximately $120,000. Cambridge Investment Research Advisors Inc. owned 0.63% of BioRestorative Therapies as of its most recent filing with the SEC. Institutional investors own 31.66% of the company's stock.BioRestorative Therapies Company Profile
(Get Rating)
BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.
Further Reading
- Get a free copy of the StockNews.com research report on BioRestorative Therapies (BRTX)
- MarketBeat: Week in Review 12/05 – 12/09
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Receive News & Ratings for BioRestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioRestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
Roth Capital initiated coverage on shares of BioRestorative Therapies (OTCMKTS:BRTX – Get Rating) in a research report sent to investors on Wednesday, The Fly reports. The firm issued a buy rating and a $15.00 price target on the stock.
据The Fly报道，Roth Capital在周三发给投资者的一份研究报告中启动了对BioRestorative Treatures(OTCMKTS：BRTX-GET Rating)股票的报道。该公司对该股发布了买入评级和15.00美元的目标价。
Separately, Maxim Group initiated coverage on BioRestorative Therapies in a report on Wednesday, September 28th. They issued a buy rating on the stock.
另外，Maxim Group在9月28日星期三的一份报告中发起了关于生物修复疗法的报道。他们对这只股票发布了买入评级。
BioRestorative Therapies Price Performance
生物修复疗法的价格表现
OTCMKTS BRTX opened at $3.16 on Wednesday. BioRestorative Therapies has a 1-year low of $2.46 and a 1-year high of $6.25. The business's fifty day moving average price is $3.16 and its 200-day moving average price is $3.27.
OTCMKTS BRTX周三开盘报3.16美元。生物修复疗法的一年低点为2.46美元，一年高位为6.25美元。该业务的50日移动均线价格为3.16美元，200日移动均线价格为3.27美元。
Institutional Inflows and Outflows
机构资金流入和流出
BioRestorative Therapies Company Profile
生物修复疗法公司简介
(Get Rating)
(获取评级)
BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.
生物修复疗法公司是一家生命科学公司，专注于使用细胞和组织方案开发再生医学产品和疗法，主要涉及成人干细胞。该公司的两个核心开发项目与治疗椎间盘/脊柱疾病和代谢紊乱有关。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on BioRestorative Therapies (BRTX)
- MarketBeat: Week in Review 12/05 – 12/09
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- 免费获取StockNews.com关于生物修复疗法(BRTX)的研究报告
- MarketBeat：回顾一周12/05-12/09
- 博通有基本面价值，收益率为3.35%
- 好市多VS亚马逊：年底摊牌
- 折扣零售商可以做好的便宜货
- 辉瑞、强生能否继续跑赢该指数？
Receive News & Ratings for BioRestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioRestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到生物修复疗法的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对BioRestorative Treatures和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧